A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer
Latest Information Update: 18 Nov 2024
At a glance
- Drugs Batoprotafib (Primary) ; Dabrafenib (Primary) ; Naporafenib (Primary) ; Rineterkib (Primary) ; Spartalizumab (Primary) ; Tislelizumab (Primary) ; Trametinib (Primary)
- Indications Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 14 Nov 2024 Status changed from active, no longer recruiting to discontinued.
- 10 Sep 2024 Planned End Date changed from 11 Oct 2024 to 31 Jan 2025.
- 10 Sep 2024 Planned primary completion date changed from 11 Oct 2024 to 31 Jan 2025.